Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate

被引：0
|
作者：
Akira Sawaki
Yasuhide Yamada
Yoshito Komatsu
Tatsuo Kanda
Toshihiko Doi
Masato Koseki
Hideo Baba
Yu-Nien Sun
Koji Murakami
Toshirou Nishida
机构：
[1] Aichi Cancer Center Hospital,Department of Gastroenterology
[2] National Cancer Center Hospital,Gastrointestinal Oncology Division
[3] Hokkaido University Hospital,Department of Gastroenterology
[4] Niigata University Hospital,Digestive and General Surgery 2 Division
[5] National Cancer Center Hospital East,Division of Gastrointestinal Oncology
[6] National Hospital Organization Kure Medical Center,Department of Surgery
[7] Kumamoto University Hospital,Department of Surgical Pathology
[8] Amgen Inc.,Department of Pharmacokinetics and Drug Metabolism
[9] Dokkyo University School of Medicine,PET Center
[10] Osaka University Hospital,Department of Digestive Surgery
来源：
Cancer Chemotherapy and Pharmacology | 2010年 / 65卷
关键词：
Motesanib; Angiogenesis inhibitor; Gastrointestinal stromal tumor (GIST);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：961 / 967
页数：6
相关论文
共 50 条
  • [11] Imatinib mesylate in treatment of advanced gastrointestinal stromal tumours
    Petricevic, B
    Vrbanec, D
    Belev, B
    Plestina, S
    Herceg, D
    Dedic-Plavetic, N
    ANNALS OF ONCOLOGY, 2005, 16 : 313 - 313
  • [12] Advanced gastrointestinal stromal tumors successfully treated with imatinib mesylate: A report of two cases
    Hasan, S
    Hassan, M
    Oke, L
    Dinh, K
    Onojobi, G
    Lombardo, F
    Dawkins, F
    Jack, M
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2003, 95 (12) : 1208 - 1210
  • [13] Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST)
    Fiore, M.
    Palassini, E.
    Fumagalli, E.
    Pilotti, S.
    Tamborini, E.
    Stacchiotti, S.
    Pennacchioli, E.
    Casali, P. G.
    Gronchi, A.
    EJSO, 2009, 35 (07): : 739 - 745
  • [14] Surgery of residual disease following imatinib mesylate in advanced gastrointestinal stromal tumors (GIST).
    Gronchi, A
    Fiore, M
    Bertulli, R
    Colecchia, M
    Tamborini, E
    Pilotti, S
    Messina, A
    Coco, P
    Stacchiotti, S
    Casali, PG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 825S - 825S
  • [15] Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function
    Bauer, S
    Hagen, V
    Pielken, HJ
    Bojko, P
    Seeber, S
    Schütte, J
    ANTI-CANCER DRUGS, 2002, 13 (08) : 847 - 849
  • [16] Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to Imatinib
    Yoo, Changhoon
    Ryu, Min-Hee
    Kang, Byung Woog
    Yoon, Shin-Kyo
    Ryoo, Baek-Yeol
    Chang, Heung-Moon
    Lee, Jae-Lyun
    Beck, Mo Youl
    Kim, Tae Won
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) : 1554 - 1559
  • [17] A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors ( GIST) following failure of at least imatinib and sunitinib
    Ganjoo, K. N.
    Villalobos, V. M.
    Kamaya, A.
    Fisher, G. A.
    Butrynski, J. E.
    Morgan, J. A.
    Wagner, A. J.
    D'Adamo, D.
    McMillan, A.
    Demetri, G. D.
    George, S.
    ANNALS OF ONCOLOGY, 2014, 25 (01) : 236 - 240
  • [18] Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors
    Chi, Ping
    Qin, Li-Xuan
    Camacho, Niedzica
    Kelly, Ciara M.
    D'Angelo, Sandra P.
    Dickson, Mark A.
    Gounder, Mrinal M.
    Keohan, Mary L.
    Movva, Sujana
    Nacev, Benjamin A.
    Rosenbaum, Evan
    Thornton, Katherine A.
    Crago, Aimee M.
    Francis, Jasmine H.
    Martindale, Moriah
    Phelan, Haley T.
    Biniakewitz, Matthew D.
    Lee, Cindy J.
    Singer, Samuel
    Hwang, Sinchun
    Berger, Michael F.
    Chen, Yu
    Antonescu, Cristina R.
    Tap, William D.
    CLINICAL CANCER RESEARCH, 2022, 28 (08) : 1507 - 1517
  • [19] Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial
    Doyon, C.
    Sideris, L.
    Leblanc, G.
    Leclerc, Y. E.
    Boudreau, D.
    Dube, P.
    INTERNATIONAL JOURNAL OF SURGICAL ONCOLOGY, 2012, 2012
  • [20] Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients
    Tatsuo Kanda
    Toshirou Nishida
    Norihito Wada
    Osamu Kobayashi
    Masakazu Yamamoto
    Akira Sawaki
    Narikazu Boku
    Masato Koseki
    Toshihiko Doi
    Yasushi Toh
    Yoshihiro Kakeji
    Toshiro Sugiyama
    Yoshito Komatsu
    Shojiro Kikuchi
    Kyoji Ogoshi
    Hitoshi Katai
    Kazuhito Miyachi
    Seiichi Hirota
    Atsushi Ohtsu
    International Journal of Clinical Oncology, 2013, 18 : 38 - 45
12345